20/20 Biolabs, Inc. (AIDX)

20/20 Biolabs, Inc. develops and sells laboratory blood tests that use artificial intelligence to help detect cancer and assess chronic disease risk. Its main product, OneTest for Cancer, is a multi-cancer early detection test that analyzes a panel of protein tumor markers with machine learning algorithms.

The company has also introduced OneTest for Longevity, which measures inflammatory biomarkers to estimate chronic disease risk and suggest lifestyle and dietary changes. Its tests are offered as laboratory-developed tests from its CLIA-certified lab in Gaithersburg, Maryland.

In addition, 20/20 Biolabs runs CLIAx, a shared certified laboratory service that allows diagnostics companies, including foreign startups, to launch tests in the United States without building their own labs. Its common stock trades on Nasdaq.